Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.42 |
| ▸ | RXRG | P48443 | 10/20 | 0.38 |
| ▸ | RXRB | P28702 | 9/20 | 0.38 |
| ▸ | RARA | P10276 | 3/20 | 0.38 |
| ▸ | RARG | P13631 | 6/20 | 0.38 |
| ▸ | RARB | P10826 | 5/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542761 | 0.84 | RXRA (0.40) | RXRARXRGRXRBRARARARG | |
| SCHEMBL6542759 | 0.84 | RXRA (0.40) | RXRARXRGRXRBRARARARG | |
| SCHEMBL14492684 | 0.81 | GSK3B (0.42) | RXRA | |
| SCHEMBL14492587 | 0.81 | PIM1 (0.46) | RXRA | |
| SCHEMBL14492661 | 0.80 | IDH1 (0.47) | RXRA | |
| SCHEMBL14492598 | 0.79 | DYRK1A (0.47) | — | |
| SCHEMBL5485141 | 0.77 | RXRA (0.49) | RXRARXRGRXRBRARARARG | |
| SCHEMBL5491326 | 0.76 | RXRA (0.43) | RXRARXRGRXRBRARARARG | |
| SCHEMBL6542003 | 0.75 | RXRA (0.44) | RXRARXRGRXRBRARARARG | |
| SCHEMBL6541564 | 0.74 | ALDH1A1 (0.46) | RXRARXRGRXRBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | PFAHL MAGNUS | 2006-07-20 | — | — | US | disclosed |
| US-7071218-B2 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | INCYTE SAN DIEGO INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6974826-B2 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1593677-A2 | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | Incyte San Diego Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1456187-A4 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1421061-A4 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6765013-B2 | ANTIPROLIFERATIVE AGENTS FOR TREATING ADIPOCYTE DIFFERENTIATION, CANCER, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CROHN'S DISEASE OR INFLAMMATORY BOWEL DISEASE | INCYTE SAN DIEGO | 2004-07-20 | — | — | US | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003043998-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | RXRA 307/4885RXRG 240/4885RXRB 301/4885 |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | RXRA 817/4885RXRG 728/4885RXRB 972/4885 |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, PC, PNLIP | RXRA 778/4885RXRG 660/4885RXRB 908/4885 |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RXRA 793/4885RXRG 744/4885RXRB 780/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | RXRA 247/4885RXRG 238/4885RXRB 232/4885 |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, GPR119, IL2 | RXRA 618/4885RXRG 641/4885RXRB 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.